UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): October 15, 2009
PFIZER
INC.
(Exact
name of registrant as specified in its charter)
Delaware
1-3619
13-5315170
(State or other
jurisdiction of
incorporation)
(Commission File
Number)
(I.R.S. Employer
Identification No.)
235 East 42nd Street
New York, New York
10017
(Zip
Code)
(Address
of principal executive offices)
Registrant s telephone number, including area code:
(212)
573-2323
Not Applicable
(Former Name or Former Address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.01. Completion of Acquisition or Disposition of Assets
On October 15, 2009, Pfizer Inc. ( Pfizer ) completed its acquisition of
Wyeth. Pursuant to the Agreement and Plan of Merger, dated as of January
25, 2009, as amended (the Merger Agreement ) among Pfizer, Wyeth and
Wagner Acquisition Corp., a wholly owned subsidiary of Pfizer ( Merger
Sub ), Merger Sub was merged with and into Wyeth (the Merger ). Wyeth
survived the Merger as a wholly owned subsidiary of Pfizer.
As a result of the Merger, each outstanding share of Wyeth common stock,
other than shares directly or indirectly held by Pfizer or Wyeth (which
were canceled as a result of the Merger), shares of restricted stock
(which are entitled to receive cash consideration pursuant to the terms
of the Merger Agreement), and shares with respect to which appraisal
rights were properly executed and not withdrawn, was converted into the
right to receive $33.00 in cash, without interest, and 0.985 of a share
of Pfizer common stock.
The foregoing description of the Merger and the Merger Agreement does
not purport to be complete and is qualified in its entirety by reference
to the Merger Agreement, which is incorporated herein by reference as
Exhibit 2.1.
Attached hereto as Exhibit 99.1 and incorporated herein by reference is
Pfizer's press release dated October 15, 2009 announcing the completion
of Pfizer s acquisition of Wyeth.
Forward-Looking Statements
This Current Report on Form 8-K (including information included or
incorporated by reference herein) includes "forward-looking statements"
within the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Such statements may
include, but are not limited to, statements about the benefits of the
merger between Pfizer and Wyeth, including future financial and
operating results, the combined company's plans, objectives,
expectations and intentions and other statements that are not historical
facts. Such statements are based upon the current beliefs and
expectations of Pfizer's management and are subject to significant risks
and uncertainties. Actual results may differ from those set forth in the
forward-looking statements. Pfizer does not undertake any obligation to
update publicly or revise any forward-looking statements. The following
factors, among others, could cause actual results to differ from those
set forth in the forward-looking statements: the possibility that the
expected synergies from the merger of Pfizer and Wyeth will not be
realized, or will not be realized within the expected time period, due
to, among other things, the impact of pharmaceutical industry regulation
and pending legislation that could affect the pharmaceutical industry;
the risk that the businesses will not be integrated successfully;
disruption from the merger making it more difficult to maintain business
and operational relationships; Pfizer's ability to accurately predict
future market conditions; dependence on the effectiveness of Pfizer's
and Wyeth's patents and other protections for innovative products; the
risk of new and changing regulation and health policies in the U.S. and
internationally and the exposure to litigation and/or regulatory
actions. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Pfizer's 2008 Annual Report on Form 10-K filed with the
Securities and Exchange Commission (the "SEC") on February 27, 2009,
Wyeth's 2008 Annual Report on Form 10-K filed with the SEC on February
27, 2009, as amended on April 30, 2009, and Pfizer s Registration
Statement on Form S-4, which was declared effective by the SEC on June
17, 2009, included in the Risk Factors section of each of these
filings, and each company's other filings with the SEC available at the
SEC's Internet site (http://www.sec.gov).
Item
9.01 Financial Statements and Exhibits
(a) Financial Statements of Businesses Acquired
(1)
The audited consolidated balance sheets of Wyeth as of December 31,
2008 and December 31, 2007 and the consolidated statements of
operations, changes in stockholders equity and cash flows for each
of the three years in the period ended December 31, 2008, and the
notes related thereto, which were included in Wyeth s Annual Report
on Form 10-K for the fiscal year ended December 31, 2008 (filed on
February 27, 2009), are filed as Exhibit 99.2 and incorporated
herein by reference.
(2)
The unaudited consolidated condensed balance sheet of Wyeth as of
June 30, 2009 and the unaudited consolidated condensed statements of
operations, changes in stockholders equity and cash flows for the
six months ended June 30, 2009 and June 30, 2008, and the notes
related thereto, which were included in Wyeth s Quarterly Report on
Form 10-Q for the quarter ended June 30, 2009 (filed on August 6,
2009), are filed as Exhibit 99.3 and incorporated herein by
reference.
(b) Pro Forma Financial Information
(1)
The unaudited pro forma condensed combined financial statements of
Pfizer and Wyeth as of and for the six months ended June 28, 2009
and for the year ended December 31, 2008 are filed as Exhibit 99.4
hereto.
(d) Exhibits
Exhibits
Description
2.1
Agreement and Plan of Merger dated as of January 25, 2009, as
amended, among Pfizer Inc., Wagner Acquisition Corp. and Wyeth
(incorporated by reference to Exhibit 2.1 to Pfizer s Current
Report on Form 8-K, filed on January 29, 2009).
99.1
Press release of Pfizer Inc. dated October 15, 2009 announcing the
completion of the acquisition of Wyeth.
99.2
The audited consolidated balance sheets of Wyeth as of December 31,
2008 and December 31, 2007 and the consolidated statements of
operations, changes in stockholders equity and cash flows for each
of the three years in the period ended December 31, 2008, and the
notes related thereto (incorporated by reference to Exhibit 13 to
Wyeth s Annual Report on Form 10-K, filed on February 27, 2009).
99.3
The unaudited consolidated condensed balance sheet of Wyeth as of
June 30, 2009 and the unaudited consolidated condensed statements of
operations, changes in stockholders equity and cash flows for the
six months ended June 30, 2009 and June 30, 2008, and the notes
related thereto (incorporated by reference to Wyeth s Quarterly
Report on Form 10-Q for the quarter ended June 30, 2009, filed on
August 6, 2009).
99.4
Unaudited pro forma condensed combined financial statements of
Pfizer and Wyeth as of and for the six months ended June 28, 2009
and for the year ended December 31, 2008.
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the
registrant has caused this report to be signed on its behalf by the
authorized undersigned.
PFIZER INC.
By:
/s/ Matthew Lepore
Matthew Lepore
Vice President, Chief Counsel Corporate Governance,
and Assistant General Counsel
Dated:
October 21, 2009
EXHIBIT INDEX
Exhibit No.
Description
2.1
Agreement and Plan of Merger dated as of January 25, 2009, as
amended, among Pfizer Inc., Wagner Acquisition Corp. and Wyeth
(incorporated by reference to Exhibit 2.1 to Pfizer s Current
Report on Form 8-K, filed on January 29, 2009).
99.1
Press release of Pfizer Inc. dated October 15, 2009 announcing the
completion of the acquisition of Wyeth.
99.2
The audited consolidated balance sheets of Wyeth as of December 31,
2008 and December 31, 2007 and the consolidated statements of
operations, changes in stockholders equity and cash flows for each
of the three years in the period ended December 31, 2008, and the
notes related thereto (incorporated by reference to Exhibit 13 to
Wyeth s Annual Report on Form 10-K, filed on February 27, 2009).
99.3
The unaudited consolidated condensed balance sheet of Wyeth as of
June 30, 2009 and the unaudited consolidated condensed statements of
operations, changes in stockholders equity and cash flows for the
six months ended June 30, 2009 and June 30, 2008, and the notes
related thereto (incorporated by reference to Wyeth s Quarterly
Report on Form 10-Q for the quarter ended June 30, 2009, filed on
August 6, 2009).
99.4
Unaudited pro forma condensed combined financial statements of
Pfizer and Wyeth as of and for the six months ended June 28, 2009
and for the year ended December 31, 2008.
-->